FOXP3 and acute myeloid leukemia: In the AML-DN group, there was a dramatically increased trend in Foxp3+ Vδ1 in the γδ T-cell subset (median: 4.21% vs. 1.31%, p = 0.000) and Foxp3+ Vδ2 in the γδ T-cell subset (median: 6.74% vs. 0.90%, p = 0.000) (Figure 2E).